# US 2022/0031632 A1 · Nanoparticle compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031632 A1
- Document ID: US20220031632A1
- Status: Published application
- Kind: A1
- Application number: 17/320,907
- Filed: 2021-05-14
- Published: 2022-02-03
- Earliest claimed: 2020-05-14
- Assignees: Op-T LLC; The Regents of the University of Colorado, a body corporate
- Applicants: Op-T LLC; The Regents of the University of Colorado, A Body Corporate
- Inventors: David H. Wagner, JR.; Martin G. Yussman; Gisela M. Vaitaitis; Charles W. Henry
- Web page: https://patentgrep.com/patent/US20220031632A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present developments provide methods and compositions for treating and/or preventing autoimmune diseases. In certain aspects, the present disclosure relates to the use of short peptides loaded inside of nanoparticle nanospheres, nanocapsules, or PEGylated nanoparticles. Additionally, peptide-metal nanoparticle drug conjugates are described and disclosed. In some embodiments, these nanoparticles, whether polymer based or metal-conjugated, when linked or coupled to bioactive peptides provided herein, may be capable of interacting with CD40 proteins or CD40 complexes, and thereby may interfere with the ability of CD40 to interact with CD154. The present disclosure also relates to the use of such nanoparticle-peptide conjugates in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present disclosure also relates to the use of such short peptides to prevent or reverse autoimmune disease, in particular in type 1 diabetes and multiple sclerosis, in individuals suffering from such diseases.

## Claims

### Claim 1

(canceled)

### Claim 2

A nanocapsule for delivering a drug, active pharmaceutical ingredient, or peptide drug, the nanocapsule comprising:
an outer layer;
a cavity area which is encapsulated by the outer layer; and
at least one of a drug, an active pharmaceutical ingredient, and/or peptide drug;
the drug, active pharmaceutical ingredient, and/or peptide drug occupying a space in the cavity area and being chemically unrestricted or unaffected by the outer layer; the drug, active pharmaceutical ingredient, and/or peptide drug being adapted to one or more of modify, alter, block, disrupt, and/or affect the interactions of CD40 protein or CD40 complex with CD154.

### Claim 3 (depends on 2)

The nanocapsule of claim 2, wherein the outer layer is made of poly(lactic-co-glycolic acid) (PLGA).

### Claim 4 (depends on 2)

The nanocapsule of claim 2, wherein the drug, active pharmaceutical ingredient, and/or peptide drug is selected from SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO:35.

### Claim 5

(canceled)

### Claim 6 (depends on 2)

A nanocapsule of claim 2 having a size between approximately 50 and 2,000 nanometers.

### Claim at position 7

7-8. (canceled)

### Claim 9 (depends on 2)

A nanocapsule of claim 2 having a spherical shape.

### Claim 10 (depends on 2)

A nanocapsule claim 2 having a tunable size.

### Claim at position 10

11-15. (canceled)

### Claim 16 (depends on 2)

The nanocapsule claim 2 wherein the nanocapsule is pegylated, wherein an IgG or a CD40 targeting ligand is conjugated or chemically connected to the polyethylene glycol of the outer surface of the nanocapsule.

### Claim at position 12

17-21. (canceled)

### Claim 22

A conjugate comprising one or more functionalized metal nanoparticles covalently linked to at least one peptide that binds CD40.

### Claim at position 14

23-28. (canceled)

### Claim 29 (depends on 22)

The conjugate of claim 22, wherein said peptide comprises an amino acid sequence selected from the group of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO:35.

### Claim 30

(canceled)

### Claim 31 (depends on 22)

The conjugate of claim 22, wherein the functionalized metal nanoparticle is selected from the group consisting of gold, silver, copper, platinum, and mixtures thereof and/or comprises zinc oxide.

### Claim at position 18

32-33. (canceled)

### Claim 34 (depends on 22)

The conjugate of claim 22, wherein the nanoparticles are in the range of 0.5 nm to 70 nm.

### Claim at position 20

35-38. (canceled)

### Claim 39 (depends on 22)

The conjugate of claim 22, wherein the peptide binds to a CD40 protein with a Kd of less than 10−6.

### Claim 40 (depends on 22)

The conjugate of claim 22, wherein the peptide affects or inhibits the interaction of CD40 and CD154.

### Claim 41

(canceled)

### Claim 42 (depends on 22)

The conjugate of claim 22, wherein the peptide binds CD40 at the site where CD40 interacts with CD154.

### Claim at position 25

43-44. (canceled)

### Claim 45 (depends on 22)

The conjugate of claim 22, wherein the nanoparticle is a poly(lactic-co-glycolic acid) (PLGA) nanoparticle.

### Claim 46 (depends on 22)

The conjugate of claim 22, wherein the nanoparticles are in the range of 0.5 nm to 100 nm.

### Claim at position 28

47-50. (canceled)

### Claim 51 (depends on 2)

A method to inhibit the interaction between a CD40 protein and a CD154 protein comprising contacting said CD40 protein with a peptide that is chemically bound to nanoparticle of claim 2, wherein the peptide that binds the CD40 protein at the CD154-binding site inhibits the interaction of said CD40 and CD154 proteins.

### Claim 52 (depends on 2)

A method of inhibiting inflammation comprising contacting a CD40 protein with a peptide that is bound to functionalized nanoparticle of claim 2, wherein the peptide binds the CD40 protein at the CD154 binding site, and/or wherein the peptide that binds the CD40 protein inhibits the interaction of CD40 and CD154 proteins.

### Claim at position 31

53-55. (canceled)

### Claim 56 (depends on 2)

A method of treating a disease or condition in a patient in need thereof, the method comprising administering to a patient the nanoparticle-peptide conjugate of claim 2.

### Claim 57 (depends on 56)

The method of claim 56, wherein the nanoparticle-peptide conjugate inhibits the interaction of CD40 and CD154 and/or wherein said compound binds the CD40 protein at the CD154-binding site.

### Claim at position 34

58-117. (canceled)
